Clinical Trial Update: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab plus ipilimumab versus pemetrexed with cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Mesothelioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Mesothelioma | Phase 3 | Status: COMPLETED | Results posted: 2021-04-14